Novartis has submitted an application to US regulators seeking permission to expand the treatment scope of its Genmab-partnered biologic Arzerra.
News
NHS England launches antibiotic incentive scheme
NHS England has launched a national programme to combat antibiotic overusage, which it describes it as “the world’s largest healthcare incentive scheme” to prevent antimicrobial resistance.
Sanofi’s biologic beats AbbVie’s Humira in RA trial
Sanofi/Regeneron’s biologic sarilumab has come out on top in a Phase III trial pitting its efficacy in improving the signs and symptoms of rheumatoid arthritis against that of AbbVie’s mega-blockbuster Humira, the world’s biggest selling drug with sales of more than $13 billion from across its various indications.
Hunt unveils moves to boost NHS safety and transparency
Health Secretary Jeremy Hunt has unveiled a range of new measures to boost safety and transparency in the NHS, including an independent Healthcare Safety Investigation Branch and legal protection for anyone giving information following a hospital mistake.
Pharma’s reputation with patient groups hits four-year high
It seems that the pharmaceutical industry’s increasing attention on patient centricity is starting to rub off on its corporate reputation, which has hit a four year-high according to findings of the latest PatientView survey.
UK pharma contributes £1bn to NHS meds bill
The pharmaceutical industry has handed over more than £1 billion to the Department of Health towards the cost of new medicines as part of the voluntary Pharmaceutical Payment Regulation Scheme (PPRS), according to new figures from the Association of the British Pharmaceutical Industry.
FDA agrees settlement in off-label ‘free speech’ case
US drugmaker Amarin has reached a settlement with the FDA allowing it to promote off-label use of its Vascepa (icosapent ethyl).
International Clinical Researcher of the Year finalists announced
PharmaTimes Media is delighted to announce the finalists for this prestigious global competition
International Clinical Researcher of the Year finalists announced
PharmaTimes Media is delighted to announce the finalists for this prestigious global competition
AZ neuromyelitis optica drug gets orphan status
US regulators have assigned AstraZeneca’s MEDI-551 Orphan Drug status as a treatment for patients with neuromyelitis optica (NMO) as well as neuromyelitis optica spectrum disorders (NMOSD).
MPs slam DH and NHS ‘complacency’ over lack of GPs
The Department of Health (DH) and NHS England have been ‘complacent’ about the health service’s ability to cope with rising demand for GPs, according to a new report.
Prophylactic use of Pfizer’s BeneFix cut haemophilia bleeds
Findings of a late-stage study show back the use of once-weekly treatment with Pfizer’s BeneFix to cut down bleeding episodes in patients with haemophilia B.
Sanofi, MSD to dismantle vaccines JV
Sanofi Pasteur and MSD have announced the end of their European vaccines joint venture so that their own “distinct growth strategies” can be pursued instead.
UK launch for Shire’s long-acting ADHD therapy
Shire has rolled out its long-acting attention deficit hyperactivity disorder drug Intuniv across the UK, extending treatment options for patients aged six to 17 years old in whom stimulant medicines are not suitable or are ineffective.
NICE minded to reject Humira for inflammatory skin disease
Cost regulators for the NHS in England and Wales are leaning towards a ‘no’ on the use of AbbVie’s Humira to treat the rare inflammatory skin disease hidradenitis suppurativa.
